Qtern

RSS

saxagliptin / dapagliflozin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Qtern. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Qtern.

For practical information about using Qtern, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 15/12/2022

Authorisation details

Product details
Name
Qtern
Agency product number
EMEA/H/C/004057
Active substance
  • Saxagliptin
  • dapagliflozin propanediol monohydrate
International non-proprietary name (INN) or common name
  • saxagliptin
  • dapagliflozin
Therapeutic area (MeSH)
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus
  • Nutritional and Metabolic Diseases
  • Metabolic Diseases
  • Glucose Metabolism Disorders
Anatomical therapeutic chemical (ATC) code
A10BD21
Publication details
Marketing-authorisation holder
Astra Zeneca AB
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
15/07/2016
Contact address
51 85 Södertälje
Sweden

Product information

06/12/2022 Qtern - EMEA/H/C/004057 - N/0037

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

  • to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,
  • when already being treated with the free combination of dapagliflozin and saxagliptin.

(See sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied.)

Assessment history

Related content

How useful was this page?

Add your rating